benzoxazoles has been researched along with azd2014 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohindra, NA; Platanias, LC | 1 |
| Behtaj, M; Dowlati, A; Fu, P; Kresak, A; Sakre, N; Wildey, G; Yang, M | 1 |
| Kirubakaran, S; Shaik, A | 1 |
| Ahmed, AR; Botchway, SW; Candeo, A; D'Abrantes, S; Needham, SR; Parker, AW; Yadav, RB | 1 |
1 review(s) available for benzoxazoles and azd2014
| Article | Year |
|---|---|
Evolution of PIKK family kinase inhibitors: A new age cancer therapeutics.
Topics: Benzamides; Benzoxazoles; Humans; Imidazoles; Molecular Targeted Therapy; Morpholines; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Signal Transduction; Triazines | 2020 |
3 other study(ies) available for benzoxazoles and azd2014
| Article | Year |
|---|---|
Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.
Topics: Benzamides; Benzoxazoles; Biocatalysis; Hematologic Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines | 2015 |
RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Benzoxazoles; Female; Fibroblast Growth Factor 10; Gene Amplification; Humans; Interleukin-7 Receptor alpha Subunit; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Morpholines; Protein Kinase Inhibitors; Pyrimidines; Rapamycin-Insensitive Companion of mTOR Protein; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2017 |
Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoxazoles; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Cricetulus; Fluorescent Dyes; Humans; Kinetics; Microscopy, Fluorescence, Multiphoton; Morpholines; Optical Imaging; Photochemotherapy; Protein Kinase Inhibitors; Pyrimidines; TOR Serine-Threonine Kinases | 2020 |